Lb Pharmaceuticals Common Stock Market Value
| LBRX Stock | 23.86 2.69 12.71% |
| Symbol | LBRX |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LB Pharmaceuticals. Expected growth trajectory for LBRX significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive LB Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding LB Pharmaceuticals Common requires distinguishing between market price and book value, where the latter reflects LBRX's accounting equity. The concept of intrinsic value - what LB Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push LB Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that LB Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LB Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LB Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
LB Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to LB Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of LB Pharmaceuticals.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in LB Pharmaceuticals on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding LB Pharmaceuticals Common or generate 0.0% return on investment in LB Pharmaceuticals over 90 days. LB Pharmaceuticals is related to or competes with Rocket Pharmaceuticals, Aura Biosciences, Annexon, Solid Biosciences, Larimar Therapeutics, Altimmune, and Autolus Therapeutics. LB Pharmaceuticals is entity of United States More
LB Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure LB Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess LB Pharmaceuticals Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.06 | |||
| Information Ratio | 0.1295 | |||
| Maximum Drawdown | 23.59 | |||
| Value At Risk | (6.59) | |||
| Potential Upside | 10.43 |
LB Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for LB Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as LB Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use LB Pharmaceuticals historical prices to predict the future LB Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1124 | |||
| Jensen Alpha | 0.7511 | |||
| Total Risk Alpha | 0.472 | |||
| Sortino Ratio | 0.168 | |||
| Treynor Ratio | (0.76) |
LB Pharmaceuticals February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1124 | |||
| Market Risk Adjusted Performance | (0.75) | |||
| Mean Deviation | 4.02 | |||
| Semi Deviation | 3.58 | |||
| Downside Deviation | 4.06 | |||
| Coefficient Of Variation | 724.37 | |||
| Standard Deviation | 5.27 | |||
| Variance | 27.81 | |||
| Information Ratio | 0.1295 | |||
| Jensen Alpha | 0.7511 | |||
| Total Risk Alpha | 0.472 | |||
| Sortino Ratio | 0.168 | |||
| Treynor Ratio | (0.76) | |||
| Maximum Drawdown | 23.59 | |||
| Value At Risk | (6.59) | |||
| Potential Upside | 10.43 | |||
| Downside Variance | 16.52 | |||
| Semi Variance | 12.84 | |||
| Expected Short fall | (4.82) | |||
| Skewness | 0.7433 | |||
| Kurtosis | 0.3941 |
LB Pharmaceuticals Common Backtested Returns
LB Pharmaceuticals appears to be slightly risky, given 3 months investment horizon. LB Pharmaceuticals Common retains Efficiency (Sharpe Ratio) of 0.18, which conveys that the company had a 0.18 % return per unit of price deviation over the last 3 months. By analyzing LB Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.96% is justified by implied risk. Please exercise LB Pharmaceuticals' Mean Deviation of 4.02, market risk adjusted performance of (0.75), and Standard Deviation of 5.27 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, LB Pharmaceuticals holds a performance score of 14. The firm owns a Beta (Systematic Risk) of -0.94, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning LB Pharmaceuticals are expected to decrease slowly. On the other hand, during market turmoil, LB Pharmaceuticals is expected to outperform it slightly. Please check LB Pharmaceuticals' potential upside, and the relationship between the jensen alpha and accumulation distribution , to make a quick decision on whether LB Pharmaceuticals' current price history will revert.
Auto-correlation | 0.55 |
Modest predictability
LB Pharmaceuticals Common has modest predictability. Overlapping area represents the amount of predictability between LB Pharmaceuticals time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of LB Pharmaceuticals Common price movement. The serial correlation of 0.55 indicates that about 55.0% of current LB Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.55 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 1.44 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for LBRX Stock Analysis
When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.